Scarica l'app Stockscreener
101.50
0.44%
-0.45
Dopo l'orario di chiusura:
101.00
-0.50
-0.49%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$101.95
Aprire:
$99
Volume 24 ore:
573.72K
Relative Volume:
0.56
Capitalizzazione di mercato:
$25.47B
Reddito:
$3.53B
Utile/perdita netta:
$-632.54M
Rapporto P/E:
-38.60
EPS:
-2.6296
Flusso di cassa netto:
$-588.89M
1 W Prestazione:
-7.92%
1M Prestazione:
-4.80%
6M Prestazione:
-9.75%
1 anno Prestazione:
-8.42%
Intervallo 1D:
$98.60
$102.10
Intervallo di 1 settimana:
$97.22
$110.10
Portata 52W:
$81.20
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
101.50 | 25.58B | 3.53B | -632.54M | -588.89M | -2.6296 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.69 | 117.06B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.86 | 80.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
717.80 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.66 | 42.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
301.12 | 32.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-06-05 | Reiterato | H.C. Wainwright | Buy |
| 2025-05-29 | Iniziato | Goldman | Neutral |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-01-10 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
| 2024-11-19 | Iniziato | Berenberg | Buy |
| 2024-11-19 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-09-24 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-14 | Iniziato | Evercore ISI | In-line |
| 2024-02-23 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-05 | Iniziato | Oppenheimer | Perform |
| 2023-12-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-17 | Aggiornamento | Redburn | Neutral → Buy |
| 2022-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-08-17 | Iniziato | Cowen | Market Perform |
| 2022-07-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2021-12-16 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Iniziato | Deutsche Bank | Hold |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-08-11 | Aggiornamento | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-06-16 | Downgrade | Redburn | Neutral → Sell |
| 2021-05-18 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-08-03 | Ripresa | Berenberg | Buy |
| 2020-07-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-30 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Iniziato | H.C. Wainwright | Neutral |
| 2020-01-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Downgrade | UBS | Buy → Neutral |
| 2019-11-05 | Iniziato | Wolfe Research | Outperform |
| 2019-11-04 | Iniziato | Berenberg | Buy |
| 2019-11-04 | Iniziato | BofA/Merrill | Buy |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-11-04 | Iniziato | JP Morgan | Overweight |
| 2019-11-04 | Iniziato | SVB Leerink | Outperform |
| 2019-11-04 | Iniziato | UBS | Buy |
Mostra tutto
Biontech Se Adr Borsa (BNTX) Ultime notizie
Is BioNTech SE (BNTX) A Good Stock To Buy Now? - Finviz
BioNTech Expands Infectious Disease Pipeline With New Mpox mRNA Vaccine Trial in Africa - TipRanks
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars - Benzinga
Sobre Bruno Hansmann - eToro
Primecap Management Co. CA Sells 130,700 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX) - The Globe and Mail
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
BioNTech’s New HIV Antibody Trial Adds Depth to BNTX’s Long-Term Pipeline Story - TipRanks
BioNTech SE (BNTX) Rallying on Solid Oncology Strategy - Finviz
BioNTech SE Sponsored ADR $BNTX Shares Sold by CenterBook Partners LP - MarketBeat
BioNTech's Strategic Pivot: Key Catalysts on the 2026 Horizon () - aktiencheck.de
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock? - Finviz
Pfizer and BioNTech Pause modRNA Shingles Ambitions - TipRanks
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data - The Globe and Mail
BioNTech (NASDAQ:BNTX) Lowered to Market Perform Rating by Leerink Partners - Defense World
Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings? - Finviz
Leerink downgrades BioNTech to “market perform” after 24% share rally - Investing.com
Lingohr Asset Management GmbH Acquires 40,821 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech and Bristol-Myers Squibb Advance Pumitamig Trial in Aggressive Brain Cancer - TipRanks
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? - The Globe and Mail
Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings? - Finviz
Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline - Finviz
BioNTech SE (BNTX): A Bull Case Theory - Finviz
2 Biotech Stocks Set to Rebound in 2026 - Finviz
Pfizer and BioNTech Move Closer to a Single-Shot Flu–COVID Vaccine: What Investors Should Watch - TipRanks
BioNTech’s New Phase III Prostate Cancer Trial Adds Long-Term Upside Potential for BNTX - TipRanks
BioNTech SE Sponsored ADR $BNTX Holdings Boosted by Lbp Am Sa - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Sector Gamma AS Has $2.74 Million Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Baillie Gifford & Co. Lowers Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig - TipRanks
Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial - TipRanks
BioNTech Shares Gain Momentum on Regulatory and Analyst Support () - aktiencheck.de
BNTX Stock Today: January 23 momentum after six-month high, 2026 catalysts - Meyka
BioNTech (BNTX) soars 11.8%: Is further upside left in the stock? - MSN
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? - Nasdaq
BioNTech (NASDAQ:BNTX) Trading 7.5% HigherHere's Why - MarketBeat
BioNTech’s BNT142 Trial Termination: What It Means for the Oncology Pipeline and Investors - TipRanks
Five Below Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? - yourwyominglink.com
What to Expect From Pfizer's Non-Oncology Business in Q4? - The Globe and Mail
BioNTech's Strategic Pivot: A Deep Dive into Its Expanding Oncology Pipeline () - aktiencheck.de
Biontech Se Adr Azioni (BNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.43%
2.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):